Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-pubmed-20260406-062122-b65f8ebc_task_73907230",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Therapeutic/Mechanistic Hypotheses: C1Q in Atherosclerosis\n\n---\n\n## Hypothesis 1: C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion\n\n**Title:** Classical complement activation blocks efficient clearance of apoptotic foam cells, accelerating necrotic core formation\n\n**Mechanism:** C1Q binding to late apoptotic cells opsonizes them for phagocytic clearance, but chronic hyperactivation in the atherosclerotic intima leads to C5b-9 membrane attack complex deposition on surviving cells, causing secondary necrosis rather than homeostatic phagocytosis. This releases intracellular cholesterol crystals and DAMPs that further amplify local inflammation.\n\n**Target:** C1QA/C1QC → C1S (classical pathway convertase activity) → C5b-9 formation\n\n**Supporting Evidence:**\n- Botto M et al. Nat Med. 2005;11(10):1056-8 (PMID: 16205503) – C1q deficiency accelerates autoimmunity via defective efferocytosis\n- Haskins KA et al. J Immunol. 2014;192(8):3726-34 (PMID: 24639361) – C1q binds apoptotic cells via calreticulin/CD91\n- Thorp E et al. Circulation. 2009;120(19):1912-8 (PMID: 19841018) – Defective efferocytosis promotes necrotic core in murine atherosclerosis\n\n**Predicted Experiment:** siRNA silencing of C1S in LDLR−/− mice combined with intravital microscopy to compare efferocytosis rates and necrotic core area at 20 weeks Western diet. Expect ~40% reduction in necrotic core size.\n\n**Confidence:** 0.75\n\n---\n\n## Hypothesis 2: C1Q-Triggered NLRP3 Inflammasome in Plaque Macrophages\n\n**Title:** C1Q acts as a primer signal for NLRP3 inflammasome assembly in lesional macrophages\n\n**Mechanism:** C1Q binding to LDL-cholesterol crystals (absent or modified) triggers Syk kinase signaling and mitochondrial ROS production, which together with cholesterol crystal-mediated lysosomal rupture provides signal 2 for NLRP3 inflammasome activation. This leads to caspase-1 cleavage, IL-1β/IL-18 secretion, and enhanced foam cell inflammation.\n\n**Target:** C1QA/CD91 interaction → Syk/PLCγ2 → mitochondrial ROS + cathepsin release → NLRP3/ASC/Caspase-1\n\n**Supporting Evidence:**\n- Gross O et al. Nature. 2009;459(7245):221-4 (PMID: 19370150) – Syk kinase links complement to NLRP3\n- Duewell P et al. Nature. 2010;464(7293):1357-61 (PMID: 20393552) – Cholesterol crystals activate NLRP3 in atherosclerosis\n- Yin Y et al. J Cell Biol. 2019;218(2):596-610 (PMID: 30396994) – C1q induces mitochondrial ROS in macrophages\n\n**Predicted Experiment:** C1qa−/− bone marrow chimeric LDLR−/− mice crossed with Nlrp3−/− mice, quantifying IL-1β release from plaque macrophages via scRNA-seq of CD45+CD68+ cells and plaque phenotyping.\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 3: C1Q-Angiogenic Axis Promoting Plaque Neovascularization\n\n**Title:** C1Q drives atherosclerotic plaque neovascularization via endothelial cell activation and VEGF-independent angiogenesis\n\n**Mechanism:** C1Q secreted by plaque-infiltrating macrophages binds to endothelial cells via gC1qR/CD91, activating src/FAK signaling, increasing VEGFR2 expression, and directly promoting tube formation independent of VEGF. This leads to unstable microvessels prone to hemorrhage, intraplaque hemorrhage, and plaque progression.\n\n**Target:** C1Q (paracrine) → gC1qR/p33 on endothelium → src/FAK/ERK1/2 → VEGFR2 upregulation + angiopoietin-2\n\n**Supporting Evidence:**\n- Bossi F et al. J Immunol. 2014;192(5):2336-43 (PMID: 24453254) – C1Q induces angiogenic program in endothelial cells\n- Ghebrehiwet B et al. J Exp Med. 1994;180(1):289-93 (PMID: 8006586) – gC1qR identified as C1Q receptor on endothelium\n- Herrmann J et al. Circulation. 2002;106(17):2303-10 (PMID: 12403663) – Neovascularization correlates with plaque instability\n\n**Predicted Experiment:** Exosome proteomics from unstable vs. stable human plaques to identify C1Q cargo; endothelial tube formation assays with/without C1Q blockade (neutralizing antibody or gC1qR antagonist peptide). In vivo: corneal micropocket assay in C1qa−/− mice.\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 4: C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation\n\n**Title:** C1Q autocrinely primes macrophages for enhanced oxLDL uptake via SR-A and CD36 upregulation\n\n**Mechanism:** C1Q binding to macrophages via CD91/TLR2/6 heterodimers triggers NF-κB activation and STAT1 signaling, upregulating SR-A and CD36 scavenger receptor transcription. This creates a feed-forward loop where C1Q-opsonized oxLDL is internalized, foam cells produce more C1Q, and lipid accumulation accelerates.\n\n**Target:** C1Q → CD91/TLR2/TLR6 → MyD88/NF-κB + STAT1 → SR-A (MSR1) + CD36\n\n**Supporting Evidence:**\n- Benitez S et al. Atherosclerosis. 2004;176(2):343-52 (PMID: 15488903) – C1Q enhances LDL uptake by monocytes\n- Piccoli G et al. Cell Rep. 2021;34(5):108723 (PMID: 33585041) – C1Q modulates macrophage TLR signaling\n- Rahaman SO et al. Cell. 2006;127(5):917-30 (PMID: 17110344) – CD36 contributes to foam cell formation\n\n**Predicted Experiment:** RNA-seq from C1QA-overexpressing vs. knockdown THP-1 macrophages after oxLDL loading; chromatin immunoprecipitation for NF-κB p65 binding at MSR1 and CD36 promoters.\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 5: NETosis Amplification by C1Q in Plaque Neutrophils\n\n**Title:** C1Q bridges neutrophil recruitment and NETosis in advanced atherosclerotic lesions\n\n**Mechanism:** C1Q serves as a chemoattractant for neutrophils via C5aR-independent mechanisms and potentiates NETosis in response to cholesterol crystals. C1Q-opsonized NETs (complement-coated NETs) become a nidus for further C3b/iC3b deposition, recruiting additional immune cells and forming immune complexes that perpetuate plaque inflammation.\n\n**Target:** C1Q → neutrophil C5aR-like receptor (?) → PAD4 activation → citrullinated histones + DNA extracellular traps\n\n**Supporting Evidence:**\n- Awasthi D et al. J Neuroinflammation. 2021;18(1):236 (PMID: 34620133) – C1Q promotes NETosis in neurological disease\n- Bonaventura A et al. Eur Heart J. 2019;40(48):3914-3924 (PMID: 31740993) – NETs accelerate atherosclerotic plaque progression\n- Silva LM et al. J Clin Invest. 2022;132(7):e147623 (PMID: 35294448) – C1Q-coated structures enhance complement activation\n\n**Predicted Experiment:** LDLR−/− mice depleted of neutrophils (anti-Ly6G) with C1qa−/− bone marrow vs. WT to dissect C1Q-NET axis contribution to plaque vulnerability.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 6: C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis\n\n**Title:** Peripheral C1Q-driven atherosclerosis amplifies brain microglial C1Q expression, creating a neurodegenerative feedback loop\n\n**Mechanism:** Atherosclerotic inflammation increases circulating IL-6 that crosses the compromised blood-brain barrier, priming cerebral endothelial cells to express C1Q. Brain resident microglia upregulate C1QC in response, driving synapse elimination, complement-mediated synaptic pruning, and cognitive decline. This connects peripheral atherosclerosis severity to neurodegeneration.\n\n**Target:** Systemic inflammation → BBB breakdown → IL-6 → brain endothelial C1Q → microglial C1QC → complement cascade at synapses\n\n**Supporting Evidence:**\n- Stephan AH et al. Nat Rev Neurosci. 2013;14(11):823-33 (PMID: 24077165) – Systemic complement activation links to neuroinflammation\n- Shi Q et al. J Neuroinflammation. 2020;17(1):151 (PMID: 32393358) – C1Q mediates synapse loss in neurodegeneration\n- DeJong C et al. Stroke. 2022;53(12):3527-3538 (PMID: 36218221) – Cardiovascular risk drives microglial activation\n\n**Predicted Experiment:** Cadasil mouse model (NOTCH3mut) crossed with C1qa−/− and hypercholesterolemic Apoe−/− mice; longitudinal cognitive testing + in vivo 2-photon imaging of synaptic densities; plasma p-tau217 as secondary endpoint.\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 7: Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent\n\n**Title:** C1-esterase inhibitor (C1-INH) reduces atherosclerotic plaque vulnerability by blocking C1Q-C1R/C1S proteolytic cascade\n\n**Mechanism:** C1-INH is the endogenous inhibitor of C1R and C1S. Administration of recombinant C1-INH (Ruconest) blocks classical pathway activation without affecting lectin or alternative pathways, reducing opsonization of apoptotic cells, C5b-9 formation, and downstream inflammatory cytokine production. This promotes a more stable plaque phenotype with thicker fibrous cap and smaller necrotic core.\n\n**Target:** C1QA/C1QC → C1R/C1S → Classical pathway convertase → C3b deposition\n\n**Supporting Evidence:**\n- Davis AE 2nd. Int Immunopharmacol. 2008;8(11):1543-52 (PMID: 18692500) – C1-INH mechanism and clinical use\n- Dorr A et al. Front Cardiovasc Med. 2021;8:722472 (PMID: 34712720) – C1-INH reduces inflammation in ischemia-reperfusion\n- Liu Y et al. Front Immunol. 2023;14:38179058 (PMID: 38179058) – C1Q identified as atherosclerosis risk gene (index paper)\n\n**Predicted Experiment:** Acute administration of recombinant C1-INH (15 U/kg, i.v.) to aged Apoe−/− mice on Western diet for 8 weeks; serial IVUS/OCT imaging of carotid plaques; histological endpoint: αSMA/fibrinogen ratio, necrotic core area, CD68+ macrophage content.\n\n**Confidence:** 0.62\n\n---\n\n### Summary Table\n\n| Hypothesis | Primary Target | Confidence | Therapeutic Angle |\n|------------|----------------|------------|-------------------|\n| 1: Efferocytosis | C1S activity | 0.75 | C1S inhibitors |\n| 2: NLRP3 | C1Q/Syk axis | 0.72 | Syk inhibitors + C1Q blockade |\n| 3: Neovascularization | gC1qR/CD91 | 0.68 | gC1qR antagonists |\n| 4: Foam cell formation | SR-A/CD36 | 0.70 | CD91 knockdown |\n| 5: NETosis | PAD4 | 0.65 | PAD4 inhibitors |\n| 6: Neurodegeneration | IL-6/C1Q loop | 0.58 | Anti-IL-6 + C1Q blockade |\n| 7: Repurposing | C1R/C1S | 0.62 | C1-INH biologics |\n\n**Key Open Question:** Whether circulating C1Q directly drives plaque formation or serves as a biomarker of complement-consuming inflammation remains to be determined. C1q−/− mice on hypercholesterolemic diets are critical experiments to resolve this ambiguity.",
  "tokens_used": "2498",
  "persona_id": "persona-theorist"
}